Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes
- 1Department of Gastroenterology, Imperial College, London, UK
- 2Institute of Cell and Molecular Science, Centre for Gastroenterology, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK
- 3Lonza, Allendale, New Jersey, USA
- Correspondence to:
Professor R J Playford
Institute of Cell and Molecular Science, Barts and The London, Queen Mary’s School of Medicine & Dentistry, Turner Street, London E1 2AD, UK;
- Accepted 30 May 2006
- Revised 18 May 2006
- Published Online First 15 June 2006
Background: Zinc carnosine (ZnC) is a health food product claimed to possess health-promoting and gastrointestinal supportive activity. Scientific evidence underlying these claims is, however, limited.
Aim: To examine the effect of ZnC on various models of gut injury and repair, and in a clinical trial.
Methods: In vitro studies used pro-migratory (wounded monolayer) and proliferation ([3H]-thymidine incorporation) assays of human colonic (HT29), rat intestinal epithelial (RIE) and canine kidney (MDCK) epithelial cells. In vivo studies used a rat model of gastric damage (indomethacin/restraint) and a mouse model of small-intestinal (indomethacin) damage. Healthy volunteers (n = 10) undertook a randomised crossover trial comparing changes in gut permeability (lactulose:rhamnose ratios) before and after 5 days of indomethacin treatment (50 mg three times a day) with ZnC (37.5 mg twice daily) or placebo coadministration.
Results: ZnC stimulated migration and proliferation of cells in a dose-dependent manner (maximum effects in both assays at 100 µmol/l using HT29 cells), causing an approximate threefold increase in migration and proliferation (both p<0.01). Oral ZnC decreased gastric (75% reduction at 5 mg/ml) and small-intestinal injury (50% reduction in villus shortening at 40 mg/ml; both p<0.01). In volunteers, indomethacin caused a threefold increase in gut permeability in the control arm; lactulose:rhamnose ratios were (mean (standard error of mean)) 0.35 (0.035) before indomethacin treatment and 0.88 (0.11) after 5 days of indomethacin treatment (p<0.01), whereas no significant increase in permeability was seen when ZnC was coadministered.
Conclusion: ZnC, at concentrations likely to be found in the gut lumen, stabilises gut mucosa. Further studies are warranted.
- ANOVA, analysis of variance
- BrdU, bromodeoxyuridine
- BSA, bovine serum albumin
- DMEM, Dulbecco’s modified Eagle medium
- EGF, epidermal growth factor
- HPLC, high-pressure liquid chromatography
- NSAID, non-steroidal anti-inflammatory drug
- RIE, rat intestinal epithelium
- ZnC, zinc carnosine
Published Online First 15 June 2006
Funding: This work was partially funded by the Wexham Park Gastrointestinal Trust grant number 2004/6772, a DDF/Belmont Trust Award, Lonza Nutrition, USA and M&M Veterinary Health, USA.
Competing interests: The use of extended health claims for ZnC is currently under consideration by the Federal Drug Administration (USA). RJP provided evidence of relevant data at their hearing.